Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast Immune Selection (BIS) preoperative randomized trial in early breast cancer
2020-004696-41Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab, bevacizumab, ipatasertib, pertuzumab and trastuzumab in breast cancer and triple-negative breast cancer (TNBC) (5 arms), sponsored by Gustave Roussy. Primary endpoints: Immune activation in paired samples and Tumor immunogenicity ratios. Started Jul 2021; status: active.
02
Drugs
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-004696-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004696-41.